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ABSTRACT
Background and the purpose of the study: Many factors have been reported that contribute to the 
wide intra- and inter-patient variability of Busulfan (Bu) disposition. The purpose of this study 
was to develop a population pharmacokinetic model and to determine the covariates affecting 
the pharmacokinetics (PK) of Bu in Iranian adult patients who received oral high-dose as a 
conditioning regimen before Hematopoietic Stem Cell Transplantation (HSCT).
Methods: A population PK analysis was performed in 30 patients who received an oral Bu and 
cyclophosphamide regimen before HSCT. Bu was given orally according to the protocol of the 
institution. In order to prevent seizures caused by Bu, phenytoin was administered orally one 
hour before each dose of Bu. 
A total of 180 blood samples were analyzed by HPLC and PK parameters were estimated by the 
non-linear mixed effect model by MONOLIX 3.1 program. A one-compartment model with an 
additive error model was used to describe the concentration-time profile of Bu. 
Results: Patients’ disease and weight was found to be the determinant factors for clearance (CL) 
and the volume of distribution (Vd) according to Monolix analysis. The covariate entered in 
final model followed by these equations:
CL=13.4[1+ (0.141×Disease)], 
Vd=42.6[1+0.010× (Weight - 63.9)]     
 In this limited study, the age (15-43 years) had no significant effect. For a patient weighting 
60 kg, the typical CL and Vd were estimated to be 13.4 l/hr and 42.6 L, respectively. The 
interindividual  variability  of  CL  and Vd  were  13.6  and  6.3%,  respectively. There  was  no 
significant metabolic induction in these four days as is evident by comparing the trough levels 
of Bu. However it should be mentioned that, one tailed t-test p-values of the days of two and 
three, two and four and three and four were 0.083, 0.069 and 0.388, respectively. 
Major conclusions: Results of this study showed that the type of disease was a determinant 
of CL and the weight of patient was a determinant of Vd for Bu population PK parameters. A 
reliable PK parameters and Css, estimated from only one plasma concentrations (5 hrs after the 
first dose), were validated. Since these methods require few sampling and are easy to be used, 
the limited sampling methods might be advantageous in the routine clinical practice. 
Keywords: MONOLIX, Phenytoin self-induction, TDM sampling, Hematopoietic stem cell 
transplantation.
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INTRODUCTION
Busulfan  (Bu),  in  combination  with  cyclo-
phosphamide, is widely used in high doses as part 
of  the  myeloablative  conditioning  regimen  prior 
to  both  allogeneic  and  autologous  bone  marrow 
transplantation  (1).  BU  is  mainly  eliminated 
through the liver where it is converted into inactive 
metabolites  by  a  glutathione-reductase-dependent 
mechanism  involving  glutathion-S-transferase 
enzymes  (2).  Renal  elimination  of  Bu  is  limited 
and  only  2%  of  the  unchanged  drug  is  excreted 
in  urine  (3).  Similar  to  most  alkylating  agents, 
BU  has  a  narrow  therapeutic  window.  The  dose-
limiting toxicity of BU in Hematopoietic Stem Cell 
Transplantation (HSCT) regimens is hepatic Veno 
Occlusive Disease (VOD), a liver toxicity with an 
216incidence varying from 0 in children with a genetic 
disease  up  to  50%  in  adults  with  hematological 
malignancies (4).
Population pharmacokinetic (PK) analysis is helpful 
to  identify  factors  that  affect  PKs  or  to  explain 
the variability of PKs in a target population (5, 6). 
Because  Bu  shows  large  individual  variability  in 
its PK in children, it would be useful to develop a 
population PK model that integrates the currently 
available  data.  Such  a  model  may  incorporate 
several factors that cause interindividual variability 
of PKs and should be useful as a tool to predict 
plasma  concentration-time  profiles  for  patients 
with different backgrounds. In the present study, a 
population PK model for oral Bu in adult Iranian 
patients was developed based on a large pool of data 
obtained during therapeutic drug monitoring.
Patients and methods
A total of 30 Iranian patients (21 male, 9 female), 
who underwent HSCT in the Hematology-Oncology 
and  Bone  Marrow  Transplantation  Research 
Center/Tehran  University  of  Medical  Sciences 
(Shariati hospital) between Dec 2007 and July 2008 
entered  the  study.  The  patients  were  treated  for 
acute  myelogenous  leukemia  (6  patients),chronic 
myelogenous leukemia (4 patients), acute lymphocytic 
leukemia (15 patients) and non-malignant disorders 
(5 patients) with Bu in combination with one or two 
other  chemotherapeutic  agents  (cyclophosphamide, 
melphalan,  thiotepa,  etoposide,  fludarabine).  The 
patients’  demographic  data  are  given  in  table  1. 
Bu was given orally three times a day for 4 days 
according to the following protocol: in Thalassemia 
(3.5mg/kg/day);  Hematologic  malignancies                                                   
(4  mg/kg/day);  Fanconi  Anemia  (1  mg/kg/day). 
It should be mentioned that, Bu was administered 
at 8 a.m., 16 p.m. and 21 p.m (not exactly every 
8 hrs). In order to prevent seizure caused by high 
dose of Bu, phenytoin at the dose of 5 mg/kg/day 
was administered orally for seven days, from the day 
before starting of the administration of Bu.
Specimen collection and storage
Patient specimens were collected for analysis at the 
following times: 1, 3, 5, 24, 48, 72 and 75 hrs after the 
first dose of Bu. Plasma was separated immediately 
and frozen at -20°C until analysis.
Plasma Bu concentration measurement
Bu  was  analyzed  by  a  minor  modification  in 
a  reported  method  trough  high  performance 
liquid  chromatography  (HPLC)  equipped  with 
a  fluorescence  detector  and  derivatization  using                       
2-naphthalenethiol (NAT)(7).
Plasma  (1  ml)  and  20  µl  of  an  internal  standard 
solution (bis [methanesulfonyloxy] pentane 1µg/ml) 
were pipetted into a tube and treated with 3 ml of 
dichloromethan. The mixture was vigorously shaken 
for 30 min and centrifuged at 4000 × g for 15 min. The 
upper aqueous phase was discarded and the organic 
phase was evaporated. The residue was dissolved in 
0.5 ml of acetone and 20 µl of NAT Solution (0.1 
M) and treated with 25 µl of 0.1 NaOH and then 
the mixture was heated at 65°C for one hour. After 
cooling, 20 µl of the resulting solution was injected 
to the HPLC system which was a Choromolith PR-
18e instrument equipped with fluorescence detector. 
The  mobile  phase  consisted  of  methanol/water 
(87.5/12.5, v/v), with a flow rate of 1.5 ml/min and 
detector was operated at an excitation wavelength 
of  350  nm  and  emission  wavelength  of  430  nm. 
Under these conditions, the retention times of Bu 
and the internal standard were 6.6 and 8.6 minutes, 
respectively (Fig. 1).
Calibration  standards  for  Bu  covering  the  range 
of  40-800  ng/ml  were  prepared  in  1  ml  of  drug-
free  plasma  and  exposed  to  the  above  extraction 
and  derivation  procedure.  The  LOQ  (Limit  Of 
Quantification)  of  the  method  was  40  ng/ml  and 
the LOD (Limit Of Detection) was 10 ng/ml. The 
calibration graph was obtained by plotting the peak-
area ratio of the drug and internal standard versus 
the  nominal  concentration  of  Bu,  (Y=0.0006x-
0.0054  R2=0.9993).  The  accuracy  and  precision 
of the method of analysis is shown in table 2, the 
inter-day and intra-day coefficients of variation were 
below 10%.  
Population pharmacokinetic statistic analysis
A population pharmacokinetic model was developed 
and fitted to the Bu concentration-time data by using 
MONOLIX (version 3.1). The minimum value of 
Table 1. Characteristics of 30 patient under study.
Gender
Male 21
Female 9
Age (year)
Mean±SD 26.2±8.1
Minimum-maximum 15-43
Weight (kg)
Mean±SD 63.9±11.8
Minimum-maximum 22-80
Dose (mg/day)
Mean±SD 233.80±64.22
Minimum-maximum 14-296
Disease
Malignant diseases 25
Other  5
Number of sampling 240
SD, standard deviation; AST, aspartate aminotransferase;
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the objective function (MOF) was used to choose 
suitable models during the model-building process. 
Because of the difference in MOF between one model 
other models approximates, and χ2 distribution with 
the degree of freedom of the number of parameters,   
there  were  two  parameters  in  the  model-building 
process and6.63 for one degree of freedom difference 
in  MOF  (P<0.01)  was  considered  statistically 
significant (8).
Base population pharmacokinetic model
One-compartment model with first-order elimination 
was used to describe the data. Both zero- and first-
order  absorption  models  with  and  without  an 
absorption lag time were tested. A two-compartment 
model was also tested. The base pharmacokinetic 
parameters  were  CL/F  (L/hr)  and  Vd/F  (l).  The 
inter-patient variability in the three fundamental PK 
Parameters (CL/F, Vd/F, and ka) were modeled with 
proportional error according to the equation: Pj = P’j 
(1+ ηj (where P’j represents the mean population 
parameters (CL/F, Vd/F, and ka), Pj represents the 
individual  parameters  for  patients  j,  and  ηj  is  an 
independently  distributed  random  variable  with 
mean zero and variance ω2.The residual variability 
was also modeled with additive error according to 
the following equation: 
Cij = Cmij + εij ,where Cij is the measured plasma 
concentration collected at time i from patient j; Cmij 
is the corresponding predicted plasma concentration 
by the model and εij is the residual variability term, 
representing  independent  identically  distributed 
statistical error with mean zero and variance σ2 for 
plasma concentrations.
Final pharmacokinetic model
The  influences  of  the  following  covariates  were 
investigated  consecutively:  age,  weight,  height, 
gender, BSA, Body Mass Index (BMI), serum Serum 
Aspartate Aminotransferase (AST) and the kind of 
disease (malignant or non-malignant).
To select the final model, the change in the minimum 
objective  function  (MOF)  as  a  goodness  of  fit 
parameter was used, and the values before and after 
a covariate to the model were compared. A decrease 
in the MOF of more than 6.63 (log likelihood ratio 
test) was considered as a significant improvement 
to the model (P<0.01). In addition, improvement in 
the fit of the data was determined by the precision 
of  the  parameter  estimates  (standard  errors)  and 
by a visual inspection of plots of data against the 
population  model  and  the  individual  predictions 
as well as plots of the data against the weighted 
residuals.
Fig1.Chromatograms A1 and A2 are for 1   g/ml internal standard and B1 and B2 are about 
a plasma sample with 1   g/ml internal standard and 400 ng/ml BU.6.6 minutes and 8.6 
minutes are the retention times of BU and  the  internal standard, respectively.
                                       +  Data;  ______Model   
fig. 2. Measured plasma concentrations data versus time. Individual model predictions 
(Model)  of  the  final  population  model  for  one  representative  patient  (ID  2) 
Figure 1. Chromatograms of A1 and A2 are for 1 µg/ml internal standard and B1 and B2 are plasma sample with 1 µg/ml internal standard 
and 400 ng/ml. Retention time for Bu and internal standard were 6.6 and 8.6 min respectively.Hadjibabaie et al / DARU 2011 19 (3) 216-223 219
Sparse sampling strategy
Since rich sampling is not only a risk for the patient 
but  also  time-  and  money-consuming,  a  sparse 
sampling strategy was evaluated. The time point of 5 
hours which was considered to cover the major part 
of the concentration-time profile after administration 
of the initial dose was used. 
 
RESULTS
Base population pharmacokinetic model
One-compartment  model  was  found  to  describe 
the  concentration-time  data  adequately.  A  two-
compartment model improved the fit of the data but 
gave unacceptable precision and inconsistencies in 
model parameters. The use of an absorption lag time 
or dependent absorption models did not increase the 
goodness-of-fit. Due to the lack of enough data in 
the  absorption  phase,  absorption  constant  ka  was 
fixed to 1.5 1/hr. Parameters of the base model are 
listed in table 3.
Final population pharmacokinetic model
The  final  PK  parameters  were  Cl/F  =13.40  L/hr, 
and Vd/F = 42.60 L. The estimated population PK 
parameters of BU are shown in table 2. The inter-
individual variabilities in C/L and Vd were 32.5 and 
20.0, respectively; and the residual variability was 
12.1%  as  the  coefficient  of  variation.  Plot  of  the 
observed Bu concentrations versus the concentrations 
predicted by the final models in a patient is shown in 
figure 2.
The  CL  parameter  was  found  to  be  significantly 
correlated with type of disease, whereas actual body 
weight was a covariate that influenced Vd of Bu. 
PK parameters were not found to be correlated to 
other covariates such as age, gender, BSA, BMI, and 
AST level. Population CL and Vd were described by 
the following equations in the final model:
Cl=13.4[1+ (0.141×Disease)] 
Vd=42.6[1+0.010× (Weight - 63.9)]   
   
These equations indicate that patients with malignant 
diseases have lower CL/F than others.
Even though the individual CL was estimated from 
all available samples, but the best result was with 
sample which obtained 5 hr after the initial dose 
Nominal Concentration (ng/ml) Obtained concentration (mean±SD) Accuracy (%) Precision (%)
Intra-assay (n=5)
40 45.00±3.46 -12.50 7.68
160 159.33±0.75 0.42 0.47
400 427.67±2.17 -6.92 0.51
Inter-assay (n=3)
40 46.33±1.15 -15.83 2.49
160 161.55±3.03 -0.97 1.87
400 426.11±2.14 -6.53 0.50
Table 3. Estimates for the base, and final model and their Relative Standard Errors (RSE).
Table 2. Accuracy and precision of the method of analysis.
Parameter
Base model MOF=2764.06
Units [Estimate (RSE %)]
relative final model MOF=2756.64 
Units [Estimate (RSE %)]
Pharmacokinetic parameters
CL (l/hr) 13.9 (7.0) 13.40 (6.0)
Vd (l) 41.0 (6.3) 42.60 (7.2)
Interpatient variability
ωCL (%) 32.5 (16) 18.2 (18)
ωVd (%) 20.0 (34) 15.8 (15)
Residual variability
σ2 (%) 39 32.1
Covariates
CLθDIS 0.14(7.2)
VdθWT    0.01(29)
θ: Estimate of covariates  
ω: inter patient variabilityPopulation Pharmacokinetics of oral high-dose Busulfan 220
in which CL was estimated 13.6 1/hr compared to 
13.27.
The correlations between the initial CL/F predicted 
from the one sample 5 hrs after the initial dose and 
CL/F of all samples are shown in figure 3. Finally the 
concentration-time profile in final model is shown in 
figure 4 and dosing scheme with unequal dose interval 
is  demonstrated.  Population  model  predicted  vs. 
observed and individual model predicted vs. observed 
Bu concentration are shown in figures 5a, b.
Effect of phenytoin
To examine the role of phenytoin as potential inducers 
of liver enzymes, the values of Bu concentrations on 
days of 2, 3, and 4 were compared using the paired t- 
test. There were no statistically significant difference 
in the values of concentrations between day 2 and 
day 3(P=0.083), day 2 and day 4 (P=0.069), and day 
3 and day 4 (P=0.388). In the patient group treated 
with phenytoin, model predicted concentrations are 
shown in table 4.
DISCUSSION 
The Bu population analysis in Iranian adult patients 
was carried out, and the effect of covariates on PK 
parameters  was  investigated.  The  type  of  disease 
and  the  weight  were  determinants  of  CL  and Vd 
respectively.  Malignant  disorders  were  a  negative 
influencing  factor  for  CL/F  when  compared  with 
an  inherited  disorder.  It  has  been  demonstrated 
that CL/F is approximately 42% higher in children 
with  inherited  disorders  as  compared  with  those 
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figure 2. Measured plasma concentrations data versus time. Individual model predictions (Model) of the final population model for one 
representative patient (ID 2). 
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with leukemia (9). Also, malignant diseases were  Also, malignant diseases were  malignant diseases were 
found to be a negative influencing factor for CL/F 
in another study (10). Since patients with malignant 
diseases  usually  receive  chemotherapy  before 
transplantation; the physical status of the patients 
is likely to be weakened by previous chemotherapy. 
Important factors were the severity of chemotherapy 
and/or the grade of liver function damage (10). 
Phenytoin  is  an  inducer  of  CYP  3A4,  a  major 
isoenzyme of the CYP 450 system that is responsible 
for  the  biotransformation  of  Bu  to  an  inactive 
metabolite (11). phenytoin increases the clearance   
of Bu by 15% or higher, possibly due to the induction 
of  glutathione-S-transferase  (12).  In  the  present 
study,  all  patients  received  phenytoin  as  seizure 
prophylaxis and therefore comparative analysis was 
impossible but there were no statistically significant 
differences in Bu concentration value between days 
of 2 and 3, days of 2 and 4 and days of 3 and 4 in 
patients treated with phenytoin. This result is similar 
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In this study, it was found that CL/F was not affected 
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(16).  In  this  study,  reliable  PK  parameters  and 
Css estimated from one plasma concentration (5 
hrs after the first dose) were validated. Using this 
method requires few samples and is easy to use, so 
the limited sampling methods are attractive in the 
routine clinical practice. 
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